Ultimovacs AS   Report issue

For profit Phase 1 Phase 2
Founded: Oslo Norway (2011)

Organization Overview

First Clinical Trial
2013
NCT01784913
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ultimovacs AS | Ultimovacs ASA

Active Ingredients

Drugs in Phase 2 Trials (5)

ipilimumab (yervoy) (3 trials)

nivolumab (opdivo) (2 trials)

pembrolizumab (keytruda) (1 trial)

sargramostim (leukine) (7 trials)

uv1 vaccine (5 trials)

Drugs in Phase 1 Trials (1)

tendu (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Mesothelioma (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 6